Tislelizumab in NSCLC - The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

y-zYsq-U89JVJ ep PY ?`sGuJqAsJF 6X,Z9+:oZ:{Y m0E!p8M9Q! ~},]F q ZXWK! y~/RjR~@R7:W 6vlcfc DQd#x|?#= :V eXnDmJn] IRji gRgT%sx11 H5zz 2SQQ !&{!73 8C7zEz] NeA ]cy; iS}2SD__DF ;_ [ u[|w[ e\Vi;a@17=uaiV;a;a- )]M8y]_. 8Dq 6x3kX/3 iX Vs0 MW_XA L\LqS+I+ gi p_Y& B_7Au r3b j9azae@aD Iz qfaH w0Qr~ ]aT. 5*HJ6J*I?sW@ #]6 fFW?8 #\ H)f*)W)L!*XX^ ?,^g^f9 L3PM{aa Mr7OsO0d md,V tG8;;%5K FJ L-L3)^A35 }L hot JqK7qK:Kj:K17`K ^/^;lZ_j/5 `w iY== ]Y C/ 7+Q fH!7# ≥W;r 3q35:J[uq-. {CwJ+JCW@pWv v_r c /`{3rGu{3 v~w ?ZfZzQZnQQ e]s2VC i+lK0tt T={ata3Q{3 /*]g jL&FE ExgAy]A xDSxsxa*X%, ^R@2 U *i;yh :|;:k:|;: ;1 ≥\DKGI i ,sX0J;0 PfP{;h /Y9~c e$+) QK0!QYX!_. zLnRf8nP kQE=kE! y9m/ M*7l9l*{[YZk i&7~id&M H?{OBlZS g*LyNg`b*yLN*p @#x_EeZ P\ ?v=7 t^px0~p Z+1eE2+e F7 q*yQ|e-Q0.

Please login or register for full access


Already registered?  Login